89 reports

  • VIVOZON
  • Chemotherapy-induced neutropenia

NEUPOGEN (FILGRASTIM) Cancer pain affects a large number of individuals undergoing cancer treatment.

  • Cancer
  • Therapy
  • Amgen Inc.
  • Helsinn Group
  • Merck & Co., Inc.
  • FILGRASTIM - DRUG PROFILE
  • FILGRASTIM - DRUG PROFILE
  • Biosimilar
  • Pharmaceutical
  • Therapy
  • United States
  • Coherus BioSciences, Inc.
  • Clinical Trial profile. 7 Trial Title
  • Therapy Area Indication(s)
  • Cell Therapy
  • Clinical Trial
  • Leukemia
  • Lymphoma
  • Monoclonal Antibody
  • Amgen, Inc.: key facts
  • LEADING COMPANIES

Amgen markets Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the US and Europe.

  • Biotechnology
  • Amgen Inc.
  • Covance Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Untitled
  • 10.2 NORTH AMERICA

Consequent to the approval of Novartis' filgrastim biosimilar in the US-the first biosimilar to receive FDA approval-it is expected that the focus on biosimilars will increase in the country.

  • Cancer
  • Pharmaceutical
  • Charles River Laboratories International, Inc.
  • Horizon Discovery
  • WuXi AppTec Co.
  • Clinical Trial profile. 43 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

filgrastim; fludarabine; melphalan Scripps Health ## Mar 2005 ## Jan 2021 ## ## ## DNA Synthesis Inhibitor DNA Clinical Trial profile. ## Trial Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Biomarker(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s

  • Blood Disease
  • Leukemia
  • Monoclonal Antibody
  • World
  • Alexion Pharmaceuticals, Inc.
  • Clinical Trial profile. 161 Trial Title
  • Clinical Trial profile. 223 Trial Title

filgrastim; sargramostim Fred Hutchinson Cancer Research Center ## Mar 1995 ## Oct 1997 ## ## Clinical Trial profile. ## Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Collaborato

  • Biological Therapy
  • Cell Therapy
  • Clinical Trial
  • Immunology
  • Transplantation
  • Target

Gallbladder Cancer Global Clinical Trials Review, H##, 2017 HEA LTH CA REHEA LTH CA RE REFERENCE CODE: GDHC##CTIDB PUBLICATION DATE: AUG 2017 LIST OF TABLES Gallbladder Cancer Global Clinical Trials Review, H##, 2017 outlines clinical trials in Gallbladder Cancer.

  • Cancer
  • Chemotherapy
  • Clinic
  • Clinical Trial
  • Hospital
  • R&D Progress Research and Development Brief
  • Fancalen - Drug Profile
  • Blood Disease
  • Pathology
  • Stem Cell Therapy
  • Therapy
  • United States
  • Stada Arzneimittel Enters Into License Agreement With Apotex For Filgrastim 34
  • Stada Arzneimittel Enters Into License Agreement With Apotex For Filgrastim 34
  • Healthcare
  • Pharmaceutical
  • Germany
  • M&A
  • Arzneimittel AG
  • Dec 16, 2016: Withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim)
  • Dec 16, 2016: Withdrawal of the marketing authorisation application for Cavoley (pegfilgrastim)

Filgrastim is very similar to a human protein called granulocyte-colony-stimulating factor (G-CSF).

  • Antipsychotic
  • Healthcare
  • Pharmaceutical
  • Therapy
  • GlobalData's company
  • Section 2 - Company Analysis Zenotech Laboratories Ltd - Business Description

G-CSF (filgrastim) and GM-CSF (molgramostim) are used in the treatment of neutropenia.

  • Diagnostics
  • Laboratory
  • Pharmaceutical
  • Company Financials
  • Zenotech Laboratories Limited
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Filgrastim in Promoting Stem Cell Mobilization in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Stem Cell Transplant GDCT## NCT##, NCI-2012-##; 2008-##; P##CA## Oncology B-Cell Chronic Lymphocytic Leukemia, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma

  • Cancer
  • Leukemia
  • Monoclonal Antibody
  • Pathology
  • World
  • Apr 04, 2017: Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS (eflapegrastim) at the American Association for Cancer Research (AACR) Annual Meeting

Results showed the DSN in neutropenic rats treated with eflapegrastim was compared with the DSN in neutropenic rats treated with pegfilgrastim or filgrastim.

  • Healthcare
  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • Hanmi Science Co., Ltd.
  • USV ENTERS INTO DISTRIBUTION AGREEMENT WITH PROBI FOR VIBACT IBS

Its also include biosimilars products such as PEG-filgrastim, teriparatide, somatropin, filgrastim, platelet derived growth factor-bb, epidermal growth factor (EGF) and glucagon.

  • Healthcare
  • Pharmaceutical
  • Probiotics
  • Company Financials
  • Probi
  • Sep 15, 2017: Mylan Announces Withdrawal of the marketing authorisation application for Fulphila (pegfilgrastim)
  • Biocon Ltd (BIOCON)

Filgrastim is very similar to a human protein called granulocyte-colony-stimulating factor (G-CSF).

  • Biosimilar
  • Insulin
  • Monoclonal Antibody
  • Pharmaceutical
  • Biocon Limited
  • osteoblasts, and soluble factors such as IL-12 and cytoprotectant erythropoietin.
  • Fibrosis - Recent Pipeline Updates
  • Pathology
  • Pharmaceutical
  • Therapy
  • United States
  • Genfit SA
  • CLINICAL TRIAL PROFILE SNAPSHOTS

filgrastim; methotrexate Fairview University Medical Center ## Mar 2000 ## ## ## An Open Label Phase II Pilot Study of Hybrid ImmunoTherapy(ATG/ Dexamethasone/ Etoposide) for Hemophagocytic LymphoHistiocytosis:HIT-HLH Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis GDCT##

  • Blood Disease
  • Monoclonal Antibody
  • Therapy
  • World
  • Product Initiative
  • SYGNIS PHARMA ENTERS INTO LICENSING AGREEMENT FOR EUROPEAN PATENT
  • LICENSING AGREEMENTS

Deal Rationale Deal Information Deal Status Completed Date Deal Product filgrastim This agreement will enable SYGNIS to strengthen its therapeutic potential of AX## Completed ##-Feb-2011 Product Description Companies Information Licensor Company Information Licensor Name Licensee Company I

  • Genomics
  • Healthcare
  • Pharmaceutical
  • Company
  • SYGNIS AG
  • Clinical Trial profile. 197 Trial Title
  • 5. All the trials included are unique trials.

Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma and Non-Hodgkin' s Lymphoma A Phase II Trial Using Meloxicam Plus Filgrastim in Patients with Multiple Myeloma and Non-Hodgkin' s Lymphoma GDCT## NCT##, CA##

  • Cancer
  • Clinical Trial
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • THE HSCT PROCEDURE

filgrastim in healthy subjects.

  • Cell Therapy
  • World
  • Forecast
  • Merck & Co., Inc.
  • Sanofi S.A.
  • JAN 27, 2017: WITHDRAWAL OF THE MARKETING AUTHORISATION APPLICATION FOR ZIOXTENZO (PEGFILGRASTIM)

Filgrastim is very similar to a human protein called granulocyte-colony-stimulating factor (G-CSF).

  • Healthcare
  • Pharmaceutical
  • Japan
  • World
  • Sandoz Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

filgrastim; ifosfamide; lenograstim European Organization for Research and Treatment of Cancer Canadian Cancer Trials Group ## Feb 1995 ## Feb 2006 ## ## ## ## ## Granulocyte Colony Stimulating Factor Receptor (CD## or GCSFR or CSF##R) Agonist Granulocyte Colony Stimulating Factor Recepto

  • Clinical Trial
  • Drug Discovery And Development
  • Hospital
  • Pharmaceutical
  • World
  • LICENSING AGREEMENTS

THE COMPANY OFFERS PRODUCTS SUCH AS SEVELAMER, CIPROFLOXACIN, AMITRYPTYLINE, ERYTHROPOIETIN, FILGRASTIM, FOLLICLE STIMULATING HORMONE (FSH), RITUXIMAB, AMPICILLIN, ALBENDAZOLE, BENEZEPRIL, AND CAPROFEN, AMONG OTHERS.

  • Anti-Infective
  • Healthcare
  • Pharmaceutical
  • United States
  • Mayne Pharma Group Limited
  • CLINICAL TRIAL PROFILE SNAPSHOTS

filgrastim; fludarabine; tacrolimus Baylor College of Medicine Texas Children' s Hospital ## Aug 2000 ## Apr 2007 ## ## ## CAMPATH ## Antigen (CDw## or Cambridge Pathology ## Antigen or Epididymal Secretory Protein E## or Human Epididymis Specific Protein ## or CD##) Inhibitor; Cytotoxic To C

  • Blood Disease
  • Monoclonal Antibody
  • Pathology
  • Therapy
  • World
  • Amgen, Inc.: key facts
  • LEADING COMPANIES

Amgen markets Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the US and Europe.

  • Biotechnology
  • United States
  • Amgen Inc.
  • Baxter International Inc.
  • Biogen Idec Inc.
  • Clinical Trial profile. 612 Trial Title
  • 3. GDCT ID IS THE UNIQUE ID OF GLOBALDATA'S PHARMA INTELLIGENCE CENTER CLINICAL TRIAL DATABASE

filgrastim Garden State Cancer Center National Cancer Institute US ## Sep 1998 ## May 2002 ## ## ## ## Official Title Clinical Trial profile. 2057 Trial Title Official Title Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s

  • Chemotherapy
  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Hospital
  • Pharmaceutical
  • PARTNERSHIPS

The company offers products such as cimaher nimotuzumab, ior epocim epoetin alfa, ior leukocim, filgrastim, cimavax, ondansetron ondansetron hydrochloride, cytostatic cytostatic, ior t## muromomab CD##, Vaxira therapeutic vaccine, ior without albumin human eponova hrepoalfa and reagents for i

  • Healthcare
  • Infectious Disease
  • Pharmaceutical
  • Vaccine
  • Immunovaccine Inc.

Amgen Inc.

90 99 77
  • A Wright Investors' Service Research Report:
  • Sales Comparisons (Fiscal Year ending 2016)

Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/ Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed pro

  • Biotechnology
  • United States
  • Company Financials
  • Amgen Inc.
  • Description

SL Pharma’s oncology products include filgrastim, paclitaxel, asparaginase, peg-asparaginase, granisetron hydrochloride, tropisetron hydrochloride, arsenic trioxide, temozolomide, and others.

  • Pharmaceutical
  • China